Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
Authors
Anderson Craig
Lavados P
Olavarría V
Bashir S
Kasner S
Barroso C
Ahmad N
Swaminathan B
Sharma M
Muir K
Veltkamp R
Ameriso S
Ameriso S
Endres M
Lutsep H
Messé S
Spence J
Nedeltechev K
Perera K
Santo G
Lindgren A
Bangdiwala S
Shoamanesh A
Berkowitz S
Mundl H
Connolly S
Hart R
Abdelhamid N
Abdul R
Abdul-Saheb M
Abreu P
Abroskina M
Abu A
Accassat S
Acciaresi M
Adami A
Ahmed F
Alberto H
Alemseged F
Ali A
Altavilla R
Alwis L
Amarenco P
Amaro S
Amaya S
Amelia P
Amin H
Amino T
Amjad A
Anagnostou E
Andersen G
Anderson D
Andrea F
Andres M
Andreu D
Androulakis M
Angel G
Angel S
Angeles D
Angels F
Anticoli S
Arauz A
Arauz G
Araya P
Arenillas L
Arias R
Arnold M
Augustin S
Avelar W
Azevedo E
Babikian V
Bacellar A
Badalyan K
Bae H
Baez M
Bagelmann H
Bailey P
Bak Z
Baker M
Balazs A
Baldaranov D
Balogun I
Balueva T
Bankuti Z
Bar M
Baranowska A
Bardutzky J
Barker T
Barlinn J
Baronnet F
Barteys M
Bartolottiova T
Barulin A
Bas M
Basile V
Bathe-Peters R
Bathula R
Batista C
Batur C
Baumgartner P
Type of Publication
Journal Article
Journal
The Lancet Neurology
DOI
10.1016/S1474-4422(18)30319-3
Number of Pages
1053 - 1060
Date Published
-31150635653
